TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04990947

Intervention type: OTHER
Intervention: lifestyle / RYGB
Description: No intervention, just 2 different groups will be included
Study: NCT06613750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants in this arm will receive metformin 500 mg to 2000 mg per day, divided into two doses, for 12 weeks
Study: NCT06612554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc acetate
Description: Participants in Control group. They will continue the SoC + 3 tablets of placebo and participants in Zinc supplementation group. Tablets will be separated 12h (just in case the ART is based in Integrase Inhibitors (INSTI)) during supplementation for 16 weeks with 3 tablets of zinc (83mg Zinc acetate/tablet).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants in Control group. They will continue the SoC + 3 tablets of placebo. 3 tablets separated 12h from ART during 16 weeks
Study: NCT06614010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection
Description: Before anesthesia induction, an iliac fascia block was administered using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, dexmedetomidine was infused intravenously at a rate of 0.5 µg/kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine and Dexmedetomidine
Description: Before anesthesia induction, an iliac fascia block was administered using a mixture of 0.375% ropivacaine and 1ug/kg dexmedetomidine (30ml) under ultrasound guidance. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride Injection
Description: Before anesthesia induction, an iliac fascia block was performed using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
Study: NCT06614140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors
Description: This intervention involves a personalized neoantigen peptide vaccine composed of peptides containing tumor-specific mutations, such as SNVs, indels, and frameshift mutations. Neoantigens are selected based on criteria that enhance expression and immunogenicity.~The vaccine is administered alongside Poly-ICLC, a TLR3 agonist, to enhance immune activation. After the initial vaccine doses, checkpoint inhibitors (e.g., anti-PD-1 or anti-PD-L1) are introduced once neoantigen-specific T-cell responses are detected, preventing immune exhaustion and sustaining a strong immune response.~During the follow-up phase, both checkpoint inhibitors and Poly-ICLC are continued to maintain immune activity and ensure a lasting anti-tumor effect.
Study: NCT06613607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Strengthening
Description: Strengthening protocol will comprise of following three phases:~Warm up phase Following exercise would be performed in warm up; Scissor skier, Criss cross crunches, , Hip circles, Bent over twist.~Strengthening:~Abdominal bracing Bracing with heel slides Bracing with leg lifts Bracing with bridging Quadruped alternate arm and leg lifts with bracing Side support with knees flexed Cool down phase: Following exercise would be performed for cood down: Child's pose, Cat cow stretch, Lower back stretch, Obliques stretch
Study: NCT06613438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eGERD device
Description: The eGERD device is a novel device developed by GerdCare Medical for reducing symptoms of GERD. The device is noninvasive and designed for self-use in the home environment. It is applied on the abdominal skin and generates electrical stimulation pulses.~For optimized effect, the stimulation is synchronized with the breathing phase, such that it is active mainly during inhalation. The stimulation intensity can be adjusted by the user.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eGERD_Sham
Description: The eGERD_Sham is a sham version of the eGERD device. It is capable of inducing sensation of electrical stimulation pulses in the target abdominal muscles without a therapeutic effect. Aside from this difference, the eGERD_Sham is identical to the eGERD device.
Study: NCT06615193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM2005
Description: HDM2005 will be administered via IV infusion.
Study: NCT06614673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text in non-narrative form
Description: Participants will be asked to read a text and complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text in narrative form
Description: Participants will be asked to read a text and complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animated video in non-narrative form
Description: Participants will be asked to watch a video and complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animated video in narrative form
Description: Participants will be asked to watch a video and complete questionnaires
Study: NCT06614894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day
Description: Ambroxol Hydrochloride 30 mg oral pill/tablet - 9 mg/kg/day
Study: NCT06614894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day
Description: Ambroxol Hydrochloride 30 mg oral pill/tablet - 18 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day
Description: Ambroxol Hydrochloride 30 mg oral pill/tablet - 27 mg/kg/day
Study: NCT06613568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moda-flx Hemodialysis System™
Description: The Moda-flx Hemodialysis System™ is a portable hemodialysis system
Study: NCT06614517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birdwatching Intervention
Description: Description: Participants will attend three birdwatching sessions, where they will enjoy direct contact with nature in selected environments such as forests and farms. These outings will be guided by an expert, who will also introduce participants to the use of binoculars and tools for identifying the birds observed during the excursions. During the outings, participants will learn the body scan technique, which will help them focus on physical sensations without making judgments. This exercise will encourage them to pay attention to details such as muscle tension, temperature, or surface contact, allowing them to be more present and connected to their surroundings during the birdwatching sessions. In addition to the in-person outings, participants will receive digital materials via WhatsApp to complement the intervention.Birdwatching Intervention
Study: NCT06613997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400mg
Description: Albendazole 400mg per days for 21 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 21 consecutive days
Study: NCT06671483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zasocitinib
Description: Zasocitinib over-encapsulated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zasocitinib
Description: Zasocitinib over-encapsulated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zasocitinib
Description: Zasocitinib over-encapsulated tablets.
Study: NCT05716399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric stimulation pretreatment
Description: Within 30 minutes before spinal anesthesia or 30 minutes after hypotension, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points, and the current intensity was only as high as the patient could comfortably tolerate (the electrical stimulation intensity was 2-3 times of the sensory threshold, for example, if the electrical stimulation intensity was 5 mA, 10-15 mA was used for stimulation), Record the specific value of current. FTEAS group pastes electrode piece, turns on the power, but there is no current output.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous acupoint electrical stimulation treatment
Description: Transcutaneous acupoint electrical stimulation treatment
Study: NCT06671483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Active comparator capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Zasocitinib or active comparator matching placebo.
Study: NCT05716399

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous acupoint pseudo electric stimulation
Description: Transcutaneous acupoint pseudo electric stimulation
Study: NCT04755231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix Presbyopia Correcting IOL
Description: UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
Study: NCT06616779

Intervention type: DEVICE
Intervention: GlucoTab
Description: Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal insulin algorithm is to maintain blood glucose (BG) within acceptable targets according to the predefined health status. For a limited time period after therapy start, three BG measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status. Nurses and nursing assistants will be trained in the use of the GlucoTab system.
Study: NCT04755231

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
Study: NCT06616779

Intervention type: OTHER
Intervention: Diabetes Treatment
Description: Diabetes Standard Care
Study: NCT06617455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT06431581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-Health intervention (educational video, SMS and reminder phone call)
Description: Pregnant women meeting the inclusion criteria and assigned to the intervention group will receive m-health intervention that includes a tailored educational video regarding perinatal care targeting positive birth outcomes and infant health, SMS messages, and reminder phone calls for follow-up
Study: NCT06640699

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.
Study: NCT06617455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO
Study: NCT06637618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: up front use of mineralocorticoid receptor antagonist
Description: the sequence of which the four drug classes are prescribed will differ, where the intervention is early use of MRA, where the control group will receive standard care, where MRA are usually prescribed last

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: up front use of mineralocorticoid receptor antagonist
Description: the sequence of which the four drug classes are prescribed will differ, where the intervention is early use of MRA, where the control group will receive standard care, where MRA are usually prescribed last
Study: NCT06136403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deucravacitinib
Description: treatment by deucravacitinib in two phases of challenge
Study: NCT05571696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immune Strength
Description: Immune Strength is a 12 week online program that provides content, strategies, and guidance on how to improve your immune system and increase your mental wellbeing, with a focus on stress, sleep, nutrition, and exercise. In addition to the online program, each participant will be paired with a Cleveland Clinic Coach who will communicate with the participant via email. The Coach will help guide the participant throughout the program and provide encouragement and guidance for making behavior changes for making a more resilient immune system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immune Strength
Description: Immune Strength is a 12 week online program that provides content, strategies, and guidance on how to improve your immune system and increase your mental wellbeing, with a focus on stress, sleep, nutrition, and exercise. In addition to the online program, each participant will be paired with a Cleveland Clinic Coach who will communicate with the participant via email. The Coach will help guide the participant throughout the program and provide encouragement and guidance for making behavior changes for making a more resilient immune system.
Study: NCT05558085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Food and Nutrition Education Program (EFNEP)
Description: Subjects will participate in nine hands-on EFNEP lessons to teach nutrition, healthy lifestyle choices, physical activity, food preparation, food safety, and food resource management.
Study: NCT05333588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: The autologous TILs will be intravenous infused into patients.
Study: NCT06617455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03088111

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of samples
Description: To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Obiltoxaximab
Description: Obiltoxaximab standard of care
Study: NCT05625893

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBT and atezolizumab/bevacizumab
Description: Atezolizumab 1200 mg and bevacizumab 15 mg/Kg is administered IV infusion every 3 weeks.~Proton beam therapy 30 - 50 Gy/5 fractions to portal vein tumor thrombosis with or without main primary tumor after 1 week (+/- 7 days) of 2nd cycle of atezolizumab and bevacizumab~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies.
Study: NCT06286358

Intervention type: DIAGNOSTIC_TEST
Intervention: Kinocardiography
Description: Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes

Intervention type: DIAGNOSTIC_TEST
Intervention: Kinocardiography
Description: Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes

Intervention type: DIAGNOSTIC_TEST
Intervention: Kinocardiography
Description: Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes
Study: NCT04768725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention combined with physical-cognitive exergaming
Description: Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\] combined with physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\].

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical-cognitive intervention
Description: Physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
Study: NCT06466655

Intervention type: OTHER
Group type: OTHER
Intervention: MitoTempol
Description: Two intradermal microdialysis probes will be inserted into the dermal layer of the ventral forearm and perfused with either lactated Ringer's solution (control) or MitoTempol (0.5 mM) to scavenge mitochondrial-derived superoxide.
Study: NCT06451263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Referral to gynecologic oncology is recommended when patients are diagnosed with a complex adnexal mass on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT). When patients are identified as having an adnexal mass, the order will be pended by the clinical research coordinator and sent to the ordering provider with a message to sign. The order will be pended within 48 hours of resulting imaging. The message will include content about national guidelines on referral to gynecologic oncology with opt-out framed language.
Study: NCT04627025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apraglutide
Description: Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Study: NCT06617455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06614088

Intervention type: DIAGNOSTIC_TEST
Intervention: serum calprotectin
Description: A blood sample is collected at time of admission to detect serum level of calprotectin

Intervention type: DIAGNOSTIC_TEST
Intervention: serum calprotectin
Description: A blood sample is collected at time of admission to detect serum level of calprotectin

Intervention type: DIAGNOSTIC_TEST
Intervention: serum calprotectin
Description: A blood sample is collected at time of admission to detect serum level of calprotectin
Study: NCT06613620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: All participants will receive 4 weeks of intervention with a frequency of 3 times/week i.e. 10minutes of hot pack followed by post facilitation stretching and strengthening protocol.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: All participants will receive 4 weeks of intervention with a frequency of 3 times/week i.e. 10minutes of hot pack followed by post facilitation stretching and strengthening protocol.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: All participants will receive 4 weeks of intervention with a frequency of 3 times/week i.e. 10minutes of hot pack followed by post facilitation stretching and strengthening protocol.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance.
Study: NCT06569381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Modified-Release Tablets
Description: take the tablet under fasting condition, 1 tablet at a time, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Modified-Release Tablets
Description: take the tablet under fed condition, 1 tablet at a time, once a day.
Study: NCT06613620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual and auditory feedback on SEMG biofeedback unit
Description: Patients will receive SEMG biofeedback assisted post facilitation stretching and strengthening. Patients will receive 50-80%of their maximum voluntary contraction as per the biofeedback and gradually the contraction time will be increased.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual and auditory feedback on SEMG biofeedback unit
Description: Patients will receive SEMG biofeedback assisted post facilitation stretching and strengthening. Patients will receive 50-80%of their maximum voluntary contraction as per the biofeedback and gradually the contraction time will be increased.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation
Description: Electrical muscle stimulation will be provided in addition to visual and auditory feedback by the SEMG biofeedback unit to the weak muscles until the patients achieve the desired level of contractions.